peptides researchCagrilintide: The Amylin Analog Quietly Reshaping Obesity Treatment

In November 2021, Daniel Lau and colleagues published the phase 2 trial of cagrilintide in The Lancet. The results were quietly remarkable: at 26 weeks, 2.4 mg weekly cagrilintide produced 10.8% mean weight loss versus 3.0% on placebo and 8.0% on liraglutide. A once-weekly amylin analog matching and exceeding a daily GLP-1 drug.

The trial did not generate the headlines tirzepatide did six months later. Amylin is a less familiar hormone than GLP-1. Novo Nordisk's commercial strategy emphasizes the combination product — CagriSema — over cagrilintide monotherapy. The amylin story has been understated.

The understatement does not match the biology. Amylin is the satiety co-signal to insulin, the meal-end message, the hindbrain stop-eating signal that GLP-1 marketing has obscured. Cagrilintide brings amylin back into clinical play after a fifteen-year hiatus since pramlintide. CagriSema is the first credible challenger to tirzepatide's dominance — and the regulatory path is now clearing.

Amylin: The Satiety Hormone That Got Buried#

Pancreatic beta cells co-secrete two peptides in response to meals: insulin and amylin. The amylin-to-insulin molar ratio is roughly 1:100. Insulin handles glucose disposal. Amylin handles three downstream effects:

1. Gastric emptying: amylin slows the rate at which the stomach empties into the small intestine. The mechanical effect of food remaining in the stomach contributes to satiety and reduces glycemic excursion.
2. Glucagon suppression: amylin suppresses postprandial glucagon. In a healthy meal response, glucagon should drop when blood glucose rises — amylin enforces this. In type 2 diabetes, this signal is impaired.
3. Central satiety: amylin receptors in the area postrema of the hindbrain — a circumventricular organ outside the blood-brain barrier — produce satiety signaling that integrates with hypothalamic pathways. This is mechanistically distinct from GLP-1's anorectic effect.

Amylin deficiency is a feature of insulin-dependent diabetes (because beta cell destruction removes both peptides) and is partially impaired in type 2 diabetes (because beta cell dysfunction affects both secretions, often unequally). Amylin replacement was the original concept behind pramlintide, approved in 2005 specifically as an adjunct to insulin in diabetes.

Pramlintide's clinical use stayed niche. Its 48-minute half-life required injection at every meal — a level of patient burden that limited adoption. The amylin pathway was right; the molecule's pharmacokinetics were wrong for chronic obesity treatment.

Cagrilintide is the same pathway, redesigned for once-weekly dosing.

The Structural Engineering Behind Long-Acting Amylin#

Native human amylin is a 37-amino-acid peptide with two structural problems for chronic therapy: it self-aggregates into amyloid fibrils (the basis of "amyloid" terminology — amylin is one of the original amyloidogenic peptides), and it has a 13-minute plasma half-life.

Cagrilintide solves both. The amino acid substitutions reduce aggregation propensity. A fatty acid side chain enables albumin binding, dramatically extending half-life to approximately 7 days. The result is a stable, weekly-dosed amylin agonist suitable for chronic obesity treatment.

The mechanism is preserved. Cagrilintide activates the amylin receptor (a heterodimer of the calcitonin receptor with receptor activity-modifying proteins, RAMP1–3) with potency comparable to native amylin. The downstream effects — gastric emptying, glucagon suppression, area postrema satiety signaling — are unchanged in character. The clinical change is durability.

REDEFINE-1: The Combination Trial#

The Lau 2021 phase 2 trial established cagrilintide monotherapy at 10.8% weight loss over 26 weeks. The phase 3 program shifted strategy. Novo Nordisk's interest is primarily in CagriSema — cagrilintide combined with semaglutide.

The mechanistic rationale: GLP-1 produces forebrain satiety (hypothalamus, brainstem nuclei) and slows gastric emptying via vagal pathways. Amylin produces hindbrain satiety (area postrema) and slows gastric emptying via direct enteric effects. Two satiety pathways, partially non-overlapping, both targeting meal cessation from different angles.

REDEFINE-1 (Novo Nordisk's phase 3 trial in adults with obesity, results released 2024) randomized over 3,400 adults to CagriSema or placebo for 68 weeks. Mean weight loss on CagriSema: 22.7%. Mean weight loss on placebo: 2.3%.

This places CagriSema in the same effect-size territory as tirzepatide — 22.7% versus 22.5% in SURMOUNT-1. The drugs are not directly compared in head-to-head trials, but the parallel populations and trial designs make rough comparison reasonable.

REDEFINE-2 examined CagriSema in obesity with type 2 diabetes and reported less weight loss (consistent with the pattern across the obesity drug class) along with strong glycemic improvement.

Mechanistic Difference: Why CagriSema Is Not Just More Semaglutide#

The clinical question is whether CagriSema produces effects that semaglutide alone does not — or whether it is simply higher-dose GLP-1 by another name.

The evidence points to genuine mechanistic addition:

Different anatomical sites: GLP-1 receptors are dense in arcuate nucleus, nucleus tractus solitarius, and dorsal vagal complex. Amylin receptors dominate the area postrema. The satiety signal is layered across distinct brain regions, not just dose-doubled at the same site.

Different gastric emptying kinetics: GLP-1 slowing of gastric emptying is partially vagally mediated and shows tachyphylaxis (the body adapts). Amylin's effect on gastric emptying is direct and shows less adaptation. CagriSema produces more durable gastric retention than semaglutide alone.

Different food preferences: animal models suggest amylin modulates hedonic feeding (food choice and reward-driven eating) somewhat distinctly from GLP-1. Whether this translates to humans is incompletely characterized.

Reduced body composition cost (preliminary): limited body composition data from CagriSema trials suggests the fat-free mass loss proportion may be slightly more favorable than semaglutide monotherapy. The data is not definitive — this is an open question and likely depends heavily on resistance training and protein intake as it does for all GLP-1 class drugs (see the tirzepatide deep-dive for the lean mass loss conversation in depth).

Dosing, Titration, and Practical Use#

The phase 3 cagrilintide dosing schedule converged on a 4-week titration to 2.4 mg weekly:

• Week 1–4: 0.25 mg weekly.
• Week 5–8: 0.5 mg weekly.
• Week 9–12: 1.0 mg weekly.
• Week 13–16: 1.7 mg weekly.
• Week 17 onward: 2.4 mg weekly (target maintenance).

For CagriSema, both components are titrated in parallel — semaglutide 0.25 → 2.4 mg weekly alongside cagrilintide 0.25 → 2.4 mg weekly. The combined GI side-effect load is the rate-limiting factor; slower titration is common in clinical practice than the trial protocol.

Subcutaneous injection, abdomen or thigh, weekly. Same handling as semaglutide.

Compounded availability: gray-market peptide suppliers offer cagrilintide. Purity verification and dose accuracy are uncertain. The combination CagriSema is rarely sold as a co-formulated compounded product — patients running it informally typically inject cagrilintide and semaglutide as separate injections on different days. This is suboptimal but workable.

Expected approval timeline: Novo Nordisk has indicated FDA submission for CagriSema in 2025 with potential approval in 2026 or 2027. Cagrilintide monotherapy commercial strategy is less clear; the combination is the primary product.

The Pramlintide Legacy: What 20 Years of Amylin Data Already Showed#

The amylin pathway is not new. Pramlintide (Symlin) was FDA-approved in 2005 for type 1 and type 2 diabetes as an adjunct to mealtime insulin. Two decades of clinical use generated a substantial evidence base that informs cagrilintide expectations.

Key findings from the pramlintide literature relevant to cagrilintide:

Postprandial glucose control: pramlintide reduced postprandial glucose excursions by approximately 30% in T1DM and 25% in T2DM. The mechanism — slowed gastric emptying and suppressed glucagon — applies identically to cagrilintide. Diabetic patients on cagrilintide should expect similar glycemic effects.

Weight loss in diabetes: pramlintide produced modest weight loss (1–2 kg over 26 weeks at 120 mcg three times daily) in diabetic populations, less than what cagrilintide produces because pramlintide was dosed for glycemic control rather than weight loss specifically. The dose-response relationship was clear — higher amylin agonism produced more weight effect.

Hypoglycemia risk: pramlintide on top of insulin substantially increased hypoglycemia risk in T1DM, requiring insulin dose reduction at initiation. This applies to cagrilintide co-administered with insulin or sulfonylureas.

Gastric emptying durability: the slowing of gastric emptying with pramlintide showed less tachyphylaxis than GLP-1-induced slowing. The body adapts less to amylin's gastric effect than to GLP-1's. This is a structural advantage for chronic therapy and likely applies to cagrilintide.

Patient acceptance: the main barrier to pramlintide adoption was the burden of mealtime injection. Cagrilintide's weekly dosing removes this barrier entirely — the same biology with dramatically better practicality.

The pramlintide experience supports the cagrilintide biological premise. The translation from short-acting to long-acting amylin therapy is not a mechanism gamble — it is a pharmacokinetic upgrade of a validated pathway.

Who Cagrilintide Suits Best#

The amylin pathway is mechanistically appropriate for several patient subgroups:

GLP-1 non-responders or partial responders: patients who lose modest weight on semaglutide or tirzepatide and plateau early may benefit from the parallel pathway. Adding amylin agonism to a GLP-1 backbone (effectively, CagriSema) addresses a non-overlapping mechanism layer.

Patients with significant postprandial glucagon dysregulation: type 2 diabetes patients with elevated postprandial glucose despite GLP-1 therapy may benefit from amylin's specific glucagon-suppressing effect.

Patients with hedonic eating patterns: animal data suggests amylin may dampen reward-driven eating somewhat distinctly from GLP-1. This is preliminary in humans but theoretically valuable.

Patients with significant GI side effects on tirzepatide: the side-effect profile of CagriSema differs from tirzepatide. Some patients tolerate one but not the other. Switching options matters in chronic obesity treatment.

Less appropriate:

Lean individuals seeking metabolic recomposition: same caveats as tirzepatide. The lean mass loss problem applies. Without resistance training and 2 g/kg protein intake, the body composition outcome is unfavorable. See DEXA tracking guide for the monitoring framework.

Patients with severe gastroparesis: amylin's gastric emptying effect compounds existing dysmotility.

Pregnancy and family history of MTC/MEN-2: the same precautions as GLP-1 class apply.